Last reviewed · How we verify

NCT05330754

Caffeine Intake Inrelation to Perioperative Analgesic Consumption

Completed Last updated 16 November 2022
What this trial tests

trial testing Caffeine intake in mg in Analgesia in 90 participants. Completed in 10 September 2022.

Timeline
20 April 2022
Primary endpoint
30 August 2022
10 September 2022

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date20 April 2022
Primary completion30 August 2022
Estimated completion10 September 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 65, any sex, with Analgesia or Caffeine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Caffeine is the most widely consumed psychoactive drug in the world. Natural sources of caffeine include coffee, tea, and chocolate. Synthetic caffeine is also added to products to promote arousal, alertness, energy, and elevated mood. We designed this prospective observational study to determine if caffeine consumption would influence intraoperative analgesic consumption

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Analgesia

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing